Cargando…

Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis

This meta-analysis aimed to analyze and compare the efficacy and safety of remifentanil and dexmedetomidine applied respectively for controlled hypotension under general anesthesia. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, SinoMed, Wanfang, and VIP databases, as well a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ning, Chen, Linmu, Liu, Lulu, Rong, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844847/
https://www.ncbi.nlm.nih.gov/pubmed/36649357
http://dx.doi.org/10.1371/journal.pone.0278846
_version_ 1784870747036975104
author Xu, Ning
Chen, Linmu
Liu, Lulu
Rong, Wei
author_facet Xu, Ning
Chen, Linmu
Liu, Lulu
Rong, Wei
author_sort Xu, Ning
collection PubMed
description This meta-analysis aimed to analyze and compare the efficacy and safety of remifentanil and dexmedetomidine applied respectively for controlled hypotension under general anesthesia. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, SinoMed, Wanfang, and VIP databases, as well as dissertations and conference papers, to obtain randomized controlled trials comparing remifentanil and dexmedetomidine applied respectively for controlled hypotension before August 23, 2021. The primary outcomes included hemodynamic profiles, surgical field score, and blood loss. Extubation time, sedation and pain score at the PACU, and perioperative adverse events were the secondary outcomes. Nine randomized controlled trials with 543 patients (272 in the dexmedetomidine group and 271 in the remifentanil group) were eventually included. This meta-analysis indicated no significant difference between dexmedetomidine and remifentanil in terms of surgical field score, blood loss, minimum values of mean arterial pressure (MD 0.24 with 95% CI [-1.65, 2.13], P = 0.80, I(2) = 66%) and heart rate (MD 0.42 [-1.33, 2.17], P = 0.64, I(2) = 40%), sedation scores at the PACU (MD -0.09 [-0.69, 0.50], P = 0.76, I(2) = 92%), and incidence of bradycardia (OR 2.24 [0.70, 7.15], P = 0.17, I(2) = 0%). Compared with remifentanil, dexmedetomidine as the controlled hypotensive agent showed a lower visual analogue score at the PACU (MD -1.01 [-1.25, -0.77], P<0.00001, I(2) = 0%) and incidence of shivering (OR 0.22 [0.08, 0.60], P = 0.003, I(2) = 0%), nausea, and vomiting (OR 0.34 [0.13, 0.89], P = 0.03, I(2) = 0%). However, extubation time was shorter in the remifentanil group (MD 3.34 [0.75, 5.93], P = 0.01, I(2) = 90%). In conclusion, dexmedetomidine and remifentanil are both effective in providing satisfactory controlled hypotension and surgical conditions. Dexmedetomidine is better in easing postoperative pain at the PACU and reducing the occurrence of shivering, nausea, and vomiting. Meanwhile, remifentanil is a fast-track anesthesia with a shorter extubation time. Given the limitations of this meta-analysis, further studies are needed for a more definitive comparison of the efficacy and safety of dexmedetomidine and remifentanil.
format Online
Article
Text
id pubmed-9844847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98448472023-01-18 Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis Xu, Ning Chen, Linmu Liu, Lulu Rong, Wei PLoS One Research Article This meta-analysis aimed to analyze and compare the efficacy and safety of remifentanil and dexmedetomidine applied respectively for controlled hypotension under general anesthesia. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, SinoMed, Wanfang, and VIP databases, as well as dissertations and conference papers, to obtain randomized controlled trials comparing remifentanil and dexmedetomidine applied respectively for controlled hypotension before August 23, 2021. The primary outcomes included hemodynamic profiles, surgical field score, and blood loss. Extubation time, sedation and pain score at the PACU, and perioperative adverse events were the secondary outcomes. Nine randomized controlled trials with 543 patients (272 in the dexmedetomidine group and 271 in the remifentanil group) were eventually included. This meta-analysis indicated no significant difference between dexmedetomidine and remifentanil in terms of surgical field score, blood loss, minimum values of mean arterial pressure (MD 0.24 with 95% CI [-1.65, 2.13], P = 0.80, I(2) = 66%) and heart rate (MD 0.42 [-1.33, 2.17], P = 0.64, I(2) = 40%), sedation scores at the PACU (MD -0.09 [-0.69, 0.50], P = 0.76, I(2) = 92%), and incidence of bradycardia (OR 2.24 [0.70, 7.15], P = 0.17, I(2) = 0%). Compared with remifentanil, dexmedetomidine as the controlled hypotensive agent showed a lower visual analogue score at the PACU (MD -1.01 [-1.25, -0.77], P<0.00001, I(2) = 0%) and incidence of shivering (OR 0.22 [0.08, 0.60], P = 0.003, I(2) = 0%), nausea, and vomiting (OR 0.34 [0.13, 0.89], P = 0.03, I(2) = 0%). However, extubation time was shorter in the remifentanil group (MD 3.34 [0.75, 5.93], P = 0.01, I(2) = 90%). In conclusion, dexmedetomidine and remifentanil are both effective in providing satisfactory controlled hypotension and surgical conditions. Dexmedetomidine is better in easing postoperative pain at the PACU and reducing the occurrence of shivering, nausea, and vomiting. Meanwhile, remifentanil is a fast-track anesthesia with a shorter extubation time. Given the limitations of this meta-analysis, further studies are needed for a more definitive comparison of the efficacy and safety of dexmedetomidine and remifentanil. Public Library of Science 2023-01-17 /pmc/articles/PMC9844847/ /pubmed/36649357 http://dx.doi.org/10.1371/journal.pone.0278846 Text en © 2023 Xu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Xu, Ning
Chen, Linmu
Liu, Lulu
Rong, Wei
Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis
title Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis
title_full Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis
title_fullStr Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis
title_full_unstemmed Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis
title_short Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis
title_sort dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844847/
https://www.ncbi.nlm.nih.gov/pubmed/36649357
http://dx.doi.org/10.1371/journal.pone.0278846
work_keys_str_mv AT xuning dexmedetomidineversusremifentanilforcontrolledhypotensionundergeneralanesthesiaasystematicreviewandmetaanalysis
AT chenlinmu dexmedetomidineversusremifentanilforcontrolledhypotensionundergeneralanesthesiaasystematicreviewandmetaanalysis
AT liululu dexmedetomidineversusremifentanilforcontrolledhypotensionundergeneralanesthesiaasystematicreviewandmetaanalysis
AT rongwei dexmedetomidineversusremifentanilforcontrolledhypotensionundergeneralanesthesiaasystematicreviewandmetaanalysis